Status:
ACTIVE_NOT_RECRUITING
PGE2/IL-22 Pathway in Various Forms of Eczema
Lead Sponsor:
NHS Lothian
Conditions:
Eczema
Eligibility:
All Genders
16+ years
Brief Summary
Objectives: Eczema is a chronic inflammatory skin condition characterised immunologically by T cellmediated inflammation. The pathogenic mechanisms involved in its development are incompletely underst...
Detailed Description
Defining a specific IL-22-mediated pathway in regulating eczema (i) Introduction: Overarching aim: Eczema is a significant chronic skin disease yet the need for targeted treatments remains largely unm...
Eligibility Criteria
Inclusion
- \-
- Eczema patients must meet criteria of one of the following groups:
- Have eczema and attend the Edinburgh Dermatology Clinic.
- The normal control patients will be matched for age and sex as closely as possible to our eczema patients.
- The participants should be able to give informed consent and should be at least 16 years of age with no upper limit.
- Psoriasis patients:
- The participants will have a diagnosis of psoriasis and attend Edinburgh Dermatology clinic.
- Controls will be age and gender matched. There is no upper age limit, but the lower age limit is 16.
- Healthy volunteers:
- The participants should have no intolerance or allergy to aspirin and no allergy/sensitivity to dithranol or DNCB.
- There is no upper age limit but the lower age limit is 16.
Exclusion
- \-
- Eczema patients:
- Treatment with systemic corticosteroids or other immune response modifying systemic drugs such as azathioprine or methotrexate 2 months before the study starts.
- Inability to give informed consent.
- Psoriasis:
- Treatment with systemic corticosteroids or other immune response modifying systemic drugs such as azathioprine or methotrexate 2 months before the study starts.
- Inability to give informed consent.
- For healthy volunteers:
- intolerance/allergy to aspirin and allergy/sensitivity to dithranol or DNCB.
- involvement in another study at the same time.
- pregnancy
Key Trial Info
Start Date :
November 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04133506
Start Date
November 4 2021
End Date
December 31 2025
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QMRI
Edinburgh, United Kingdom